中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
17期
103-104,105
,共3页
慢性乙型肝炎%阿德福韦酯%恩替卡韦
慢性乙型肝炎%阿德福韋酯%恩替卡韋
만성을형간염%아덕복위지%은체잡위
chronic hepatitis B%adefovir ester%entecavir
目的：观察恩替卡韦治疗耐阿德福韦酯慢性乙型肝炎的疗效。方法随机选取2012年1月至2013年1月肝病门诊就诊的耐阿德福韦酯慢性乙型肝炎患者46例，停用阿德福韦酯，改用恩替卡韦分散片，用量0.5 mg/d，于治疗前及治疗后12周、24周、36周、48周检测肝功能、乙肝标志物等指标。结果治疗后第48周，患者HBV-DNA水平低于检测下限（<5.00×102拷贝/mL）者，乙型肝炎病毒e抗原( HBeAg )阳性组25例，HBeAg阴性组19例，组间比较差异无统计学意义（ P＞0.05）；治疗后第12周、24周、36周、48周，患者ALT复常率HBeAg阳性组分别为46.15%，53.85%，88.46%，96.15%，HBeAg阴性组分别为35.00%，50.00%，85.00%，90.00%，组间比较差异无统计学意义（ P＞0.05）；治疗后第12周、24周、36周、48周，HBeAg阳性组HBeAg阴转率分别为26.92%，38.46%，46.15%，57.69%，HBeAg血清学转换率分别为34.62%，50.00%，61.54%，73.08%，其中12周与48周比较差异有统计学意义（ P<0.05）。结论采用恩替卡韦治疗耐阿德福韦酯慢性乙型肝炎患者，疗效显著且不良反应少，值得推广。
目的：觀察恩替卡韋治療耐阿德福韋酯慢性乙型肝炎的療效。方法隨機選取2012年1月至2013年1月肝病門診就診的耐阿德福韋酯慢性乙型肝炎患者46例，停用阿德福韋酯，改用恩替卡韋分散片，用量0.5 mg/d，于治療前及治療後12週、24週、36週、48週檢測肝功能、乙肝標誌物等指標。結果治療後第48週，患者HBV-DNA水平低于檢測下限（<5.00×102拷貝/mL）者，乙型肝炎病毒e抗原( HBeAg )暘性組25例，HBeAg陰性組19例，組間比較差異無統計學意義（ P＞0.05）；治療後第12週、24週、36週、48週，患者ALT複常率HBeAg暘性組分彆為46.15%，53.85%，88.46%，96.15%，HBeAg陰性組分彆為35.00%，50.00%，85.00%，90.00%，組間比較差異無統計學意義（ P＞0.05）；治療後第12週、24週、36週、48週，HBeAg暘性組HBeAg陰轉率分彆為26.92%，38.46%，46.15%，57.69%，HBeAg血清學轉換率分彆為34.62%，50.00%，61.54%，73.08%，其中12週與48週比較差異有統計學意義（ P<0.05）。結論採用恩替卡韋治療耐阿德福韋酯慢性乙型肝炎患者，療效顯著且不良反應少，值得推廣。
목적：관찰은체잡위치료내아덕복위지만성을형간염적료효。방법수궤선취2012년1월지2013년1월간병문진취진적내아덕복위지만성을형간염환자46례，정용아덕복위지，개용은체잡위분산편，용량0.5 mg/d，우치료전급치료후12주、24주、36주、48주검측간공능、을간표지물등지표。결과치료후제48주，환자HBV-DNA수평저우검측하한（<5.00×102고패/mL）자，을형간염병독e항원( HBeAg )양성조25례，HBeAg음성조19례，조간비교차이무통계학의의（ P＞0.05）；치료후제12주、24주、36주、48주，환자ALT복상솔HBeAg양성조분별위46.15%，53.85%，88.46%，96.15%，HBeAg음성조분별위35.00%，50.00%，85.00%，90.00%，조간비교차이무통계학의의（ P＞0.05）；치료후제12주、24주、36주、48주，HBeAg양성조HBeAg음전솔분별위26.92%，38.46%，46.15%，57.69%，HBeAg혈청학전환솔분별위34.62%，50.00%，61.54%，73.08%，기중12주여48주비교차이유통계학의의（ P<0.05）。결론채용은체잡위치료내아덕복위지만성을형간염환자，료효현저차불량반응소，치득추엄。
Objective To study the effect of entecavir ( ETV ) for treating adefovir ester ( ADV ) resistant chronic hepatitis B. Methods 46 cases of ADV resistant chronic hepatitis B in the liver diseases clinic from January 2012 to January 2013 were randomly selected, stopped ADV and switched to ETV, 0. 5 mg/d. The liver function, ATL, 5 items of hepatitis B, HBV DNA and HBV markers were de-tected before treatment and at 12, 24, 36, 48 weeks after treatment. The curative effect of ETV was analyzed. Resuts The HBV-DNA levels at 48 weeks after treatment in 25 cases of the HBeAg positive group and 19 cases of the HBeAg negative group were below the lower detection limit (<5. 00 × 102 IU/mL ) , the difference between before and after treatment in the two groups had statistical signifi-cance. The comparison between the HBeAg positive group and the HBeAg negative group showed no statistical difference ( P>0. 05 ) . The HBeAg positive group were 46. 15%, 53. 85%, 88. 46% and 96. 15% respectively;the HBeAg negative group were 35. 00%, 50. 00%, 85. 00% and 90. 00% respectively, there was no statistically significant difference between the two groups ( P>0. 05 ) , the difference be-tween before and after treatment in the two groups was statistically significant;the negative conversion rates at 12, 24, 36, 48 weeks after treatment in the HBeAg positive group were 26. 92%, 38. 46%, 46. 15%, 57. 69% respectively, the HBeAg serological conversion rates at 12, 24, 36, 48 weeks after treatment were 34. 62%, 50. 00%, 61. 54% and 73. 08% respectively, in which comparing 12 weeks and 48 weeks showed the statistical difference ( P<0. 05 ) . Conclusion Adopting ETV for treating ADV resistant chronic hepatitis B has distinct effect, less adverse reaction and good safety.
